No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, l...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jonathan Z, Sax, Paul E, Marconi, Vincent C, Fajnzylber, Jesse, Berzins, Baiba, Nyaku, Amesika N, Fichtenbaum, Carl J, Wilkin, Timothy, Benson, Constance A, Koletar, Susan L, Lorenzo-Redondo, Ramon, Taiwo, Babafemi O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419983/
https://www.ncbi.nlm.nih.gov/pubmed/30895201
http://dx.doi.org/10.1093/ofid/ofz056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419983/
https://www.ncbi.nlm.nih.gov/pubmed/30895201
http://dx.doi.org/10.1093/ofid/ofz056

Ejemplares similares